Fig. 2: KPT-330-downregulated Mcl-1 facilitates mitochondria-mediated apoptosis upon KPT-330 and A-1331852. | Cell Death & Disease

Fig. 2: KPT-330-downregulated Mcl-1 facilitates mitochondria-mediated apoptosis upon KPT-330 and A-1331852.

From: XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis

Fig. 2

a U251 and H1299 cells expressing Mcl-1 (T92A) were treated with KPT-330 (1 μM) for 24 h and further with A-1155463 (1 μM) or A-1331852 (1 μM) for 24 h, then subjected to western blot or flow cytometry analysis for the sub-G1 phase (mean ± SD, n = 3). *P < 0.05. b H1299 cells expressing Mcl-1 (T92A) were treated KPT-330 (1 μM) for 3 or 4 days and subjected to flow cytometry analysis for the sub-G1 phase (mean ± SD, n = 3). *P < 0.05. c U251 and H1299 cells were treated with KPT-330 (1 μM) for 24 h and further with A-1331852 (1 μM) for 6 h. Total and active forms of Bax and Bak in cell lysates were immunoprecipitated followed by western blot. d, e U251 and/or H1299 cells expressing shBax and shBak were treated as in a and subjected to western blot (d), flow cytometry analysis for the sub-G1 phase (d), or mitochondria membrane potential (e) (mean ± SD, n = 3). *P < 0.05. f, g U251 and H1299 cells expressing shBim and/or shNoxa were treated with KPT-330 (1 μM) for 24 h and further with A-1331852 (1 μM) for 6 h or 24 h, then subjected to western blot (6 h) or flow cytometry analysis (24 h) for the sub-G1 phase (mean ± SD, n = 3). *P < 0.05. GAPDH was used as the loading control

Back to article page